Reduced-intensity conditioning for hematopoietic cell transplantation of chronic granulomatous disease

Pediatric Blood and Cancer

Volumn 62, Issue 2, 2015, Pages 359-361

  Oshrine, Benjamin ^a   Morsheimer, Megan ^a   Heimall, Jennifer ^a   Bunin, Nancy ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Chronic granulomatous disease; Hematopoietic cell transplantation; Primary immunodeficiency; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; FOSCARNET; GANCICLOVIR; STEROID; CYBB PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VIDARABINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BONE MARROW APLASIA; BONE MARROW TRANSPLANTATION; CASE REPORT; CHILD; CHIMERA; CHRONIC GRANULOMATOUS DISEASE; COLITIS; CYTOMEGALOVIRUS INFECTION; DIZYGOTIC TWINS; EMPYEMA; FEVER; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; LUNG DISEASE; LYMPHADENITIS; NONSENSE MUTATION; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT FEVER; REDUCED INTENSITY CONDITIONING; RESPIRATORY DISTRESS; VIRUS REACTIVATION; WHOLE BODY RADIATION; ANALOGS AND DERIVATIVES; GENETICS; GRAFT VS HOST DISEASE; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MORTALITY; PROCEDURES; TRANSPLANTATION CONDITIONING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; BUSULFAN; CHILD, PRESCHOOL; GRAFT VS HOST DISEASE; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 84927520973     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25225     Document Type: Article

References (11)

1. Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363:2600-2610.
2. Jones LB, McGrogan P, Flood TJ, et al. Special article: Chronic granulomatous disease in the United Kingdom and Ireland: A comprehensive national patient-based registry. Clin Exp Immunol 2008; 152:211-218.
3. van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease: The European experience. PLoS One 2009; 4:e5234.
4. Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: A survey of the European experience, 1985-2000. Blood 2002; 100:4344-4350.
5. Schuetz C, Hoenig M, Gatz S, et al. Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease. Immunol Res 2009; 44:35-41.
6. Martinez CA, Shah S, Shearer WT, et al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol 2012; 129:176-183.
7. Soncini E, Slatter MA, Jones LB, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009; 145:73-83.
8. Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105:879-885.
9. Horwitz ME, Barrett AJ, Brown MR, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001; 344:881-888.
10. Gungor T, Halter J, Klink A, et al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation 2005; 79:1596-1606.
11. Gungor T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: A prospective multicentre study. Lancet 2014; 383:436-448.